BACKGROUND: Dextromethorphan (DM) is an N-methyl-D-aspartate (NMDA) receptor antagonist that may be useful during opiate addiction process, especially in reducing methadone consumption in methadone maintenance therapy (MMT). The goal of the current study was to evaluate the effects of oral administration of DM on reducing methadone dose in MMT used to treat illicit opioid drug abuse.
J Res Med Sci 2011; 16(10) : 1354-1360 ethadone is a synthetic opioid with long acting effect which is frequently administrated to treat acute opioid withdrawal symptoms. Methadone maintenance therapy (MMT) is one of the most common methods of long-term treatment of illicit opioid abuse. 1 MMT has been customary in Iran for treatment of opioid addiction. A systematic review of randomized controlled trials has shown that higher methadone doses were more effective than doses under 60 mg in both retention on maintenance treatment and reduction of illicit drug use. 2 However, parallel to treatment with methadone, another phenomenon named tolerance is acting. In many cases, tolerance is induced during MMT and methadone dosage consumption enhances. 1, 3, 4 Although it was supposed that negative autoregulation was responsible for tolerance creation, the activation of N-methyl-D-aspartate (NMDA) receptors has been proved to have an essential role in opioid tolerance. NMDA re-M www.mui.ac.ir ceptor antagonists have the ability to inhibit the development of opiate tolerance and dependence. [5] [6] [7] In addition, NMDA receptor antagonists can indeed inhibit tolerance to different mu opioids. 5, 7 Many studies demonstrated that the combination of an NMDA-receptor antagonist and morphine decrease analgesic tolerance of morphine. 5, [7] [8] [9] Some NMDA-receptor antagonists like dextromethorphan (DM) have been used for tolerance reduction in MMT. 10 However, few studies investigated DM usage in lack of tolerance to methadone during MMT. Therefore, there is a need to further explore the effects of NMDA receptor antagonists on the development of tolerance and sensitization to opiates. The aim of the current study was to evaluate the effect of oral administration of DM for reducing methadone dose in MMT of illicit opioid abuse. Additionally, we compared the side effects of DM and assessed patients' quality of life.
Methods

Design:
A double blind randomized controlled clinical trial was conducted from January 2009 to January 2010. The study design is shown in Figure 1 . Participant recruitment: All participants were selected from substance abuse clinic at Noor hospital associated with Isfahan University of Medical Sciences. Sample size was calculated based on two mean comparison formula and 95% confidence and 80% power. The effect size was considered based on the range of methadone consumption between 30 to 120 mg. Overall, 72 patients with opium addiction were included and divided into two groups of 36. A researcher conducted the eligibility check using the abovementioned criteria and explained what would happen in the two arms of the trial and the randomization process. After the researcher summarized the information in the participant information sheet and responded to the questions about the study, the participants provided written consents. Then, participants were randomly allocated into two arms by a computer software. Every patient took a 4-digit code. Finally, EPI-6 software was used to randomly allocate the subjects into two groups of intervention and control. Only the main researcher knew about the code of allocated individuals. Evaluations were done by another investigator who was blinded regarding the allocation.
Procedure:
In the beginning, all participants underwent laboratory liver function, serum BUN and creatinine tests to check liver and renal function. After randomization, the first group received 60 mg DM daily for 4 days. Then, the dose was increased to 120 mg daily (60mg/12h) for 4 days. In the third 4-day period, DM dosage was increased to 240 mg daily (120mg/12h) which continued through the next 6 weeks. However, in the other group (considered as control), the subjects were receiving placebo using the same process in the intervention group. DM and placebo were both made by School of Pharmacy at Isfahan University of Medical Sciences. 12 This questionnaire was adapted for Iranian patients and has been applied in several studies. [13] [14] [15] The average methadone consumption was registered by the researchers in data sheets. First evaluation was done at the onset of the study to provide baseline data. Second evaluations were done every two weeks until 6 weeks after the study was started. 
Measurements
Results
Seventy two patients completed all the followup stages of this study. All participants were male. The range of age was 20-52 years (mean = 31.2 ± 7). Table 1 shows demographic characteristics of participants in the two groups. As shown, no significant differences were found between the intervention and placebo groups. The mean of methadone consumption during follow-up is demonstrated in Figure 2 . Totally, the mean of methadone consumption in DM and control groups were 62.7 mg/day (95% CI of mean: 52.7-72.7) and 70.4 mg/day (95% CI of mean: 60.4-80.4), respectively. There were not any significant differences between the two groups regarding methadone dosage. Repeated measure of ANOVA did not show any statistically significant difference between the two groups among the four evaluations made (F = 1.192; P = 0.279).
After 6 weeks of fallow-up, the difference of SOWS scores was not significant between the DM and placebo groups (F = 2.98; P = 0.09). The mean SOWS scores for each group were 9.2 (95% CI of mean: 6.8-11.5) vs. 12.1 (95% CI of mean: 9.7-14.4), respectively. Table 2 shows the frequency of withdrawal symptoms in participants. The most frequent symptom was yawning in both groups. There were no significant differences between the two groups regarding any of the withdrawal symptoms Illness  21  20  23  18  20  22  22  16  Tenesmus  7  11  10  7  11  12  12  12  Rigidity  10  14  16  12  20  18  19  20  Cold sensation  18  15  15  11  22  21  19  20  Palpitation  12  14  13  7  15  9  14  14  Bodily pain  15  17  16  12  20  13  18  18  Yawning  23  22  23  22  27  22  17  23  Insomnia  13  12  11  6  17  15  11  17  Diarrhea  2  6  4  7  9  4  7  6  Depression  19  24  22  19  24  22  17  19  Anxiety  21  26  20  16  23  22  17  17  Agitation  19  24  23  16  22  22  18  21  Irritability  13  19  17  15  20  15  19  19  Desire to substance abuse  10  22  12  10  15 19 19 22 * Comparison of each symptom between the two groups was done by Fisher's exact test. Comparison between each measure in each group was done by Friedman test. (Fisher's exact test p > 0.05). The changes in withdrawal symptoms during the 6-week follow-up were checked in every group by Friedman test. There was not any significant difference in symptoms during 6 weeks in each group. Assessment of QOL declared the mean scores of QOL during the 6 weeks of follow-up to be higher in the intervention group. Total mean score of QOL in the intervention and control groups were 84.8 (95% CI of mean: 78.7-90.8) and 77.8 (95% CI of mean: 71.8-83.7), respectively. Neither the difference between QOL scores in the intervention and control groups (F = 2.671; P = 0.107) nor the trend of QOL during 6 weeks (F = 1.566; P = 0.2) were statistically significant in the two groups (Figure 3 ).
Discussion
Findings of the present study showed the combination of methadone and DM not to statistically decrease dose of methadone consumption in MMT program participants. Likewise, statistically significant differences were not observed in the QOL between the two groups. DM and methadone are NMDA receptor antagonists. 6 DM may represent as an adjuvant medication in methadone replacement therapy. It is broadly involved in opiate-induced plasticity, including the development of methadone tolerance and sensitization. 5, 8 The inclusion of low-dose DM to methadone might be beneficial for the reduction of methadone dosage during MMT. 2, 8, 16, 17 In the current study, the maximum dose of DM was 240 mg daily and the follow-up period lasted for 6 weeks. In contrast to our findings, Cornish et al. found a significant relation between methadone reduction dosage and DM medication. However, they had prescribed 480 mg DM daily and followed the patients for only two weeks. Like our study, they could not find a significant difference between the placebo and DM groups. 10 We also analyzed the QOL and found that subjects in the DM group had higher QOL than those in the control group, though the difference was not statistically significant. There were many advantages in this study. First, with the exact quality control, the study benefitted from a high-quality methodology. In addition, the appropriate sample size, which was estimated by exact statistical formula, increased the power of the study to detect small differences between the groups. Finally, it should be noted that statistical multivariate tests were considered significant if type I error was less than 0.05 (α < 0.05).
At the end, although DM might be useful for opioid dependence treatment due to its effects in improving opiate tolerance, reducing withdrawal symptoms experienced during detoxification, and inhibiting conditioned reactions to drug-related stimuli (which play an important role in drug seeking and relapse following treatment), 10 our study could not demonstrate this effect. Therefore, further studies investigating this possibility are needed.
On the other hand, there were some limitations in our study. We had some resource and time limitations to evaluate patients using other questionnaires including those assessing personality, mood, and mental status. While we administered low dose DM (240mg/d), another study administered it at 480 mg/d. 10 We tried to use homogenous administration of methadone and although the mean dosage of methadone differed in the two groups, it was not statistically significant.
